Key result
Postoperative high-sensitivity cardiac troponin I elevation in revascularized coronary patients undergoing noncardiac surgery was associated with increased all-cause death (HR 2.80; 95% CI 1.01-7.77; p=0.048).
Why the study?
Whether perioperative high-sensitivity cardiac troponin elevation is associated with poor clinical outcomes in revascularized coronary patients undergoing noncardiac surgery remains unclear.
Does elevated postoperative hs-cTnI increase the risk of all-cause death in revascularized coronary patients undergoing noncardiac surgery?
Cohort
Does elevated postoperative hs-cTnI increase the risk of all-cause death in revascularized coronary patients undergoing noncardiac surgery?
Hazard Ratio: 2.8 (95% CI 1.01–7.77)
Absolute Event Rate: 14.9% vs 5.9%
p-value: p=0.048
Postoperative, but not preoperative, high-sensitivity cardiac troponin I elevation is associated with increased long-term all-cause mortality in patients with prior coronary revascularization undergoing noncardiac surgery.
May flag higher-risk patients for surveillance; extends observations to revascularized patients but leaves open whether interventions improve survival.
BACKGROUND: Whether high-sensitivity cardiac troponin elevation during the perioperative period is associated with poor clinical outcome in revascularized coronary patients who undergo noncardiac surgery remains unclear. We investigated the effects of perioperative troponin elevation on the long-term clinical outcomes of patients with a history of coronary revascularization. METHODS: We analyzed patients whose pre- or postoperative high-sensitivity cardiac troponin I (hs-cTnI) assay results were available. Patients were divided into two groups according to hs-cTnI levels. The patient groups were analyzed separately according to whether hs-cTnI was assessed preoperatively or postoperatively. The primary outcome was all-cause death during the follow-up period. RESULTS: Median follow-up duration was 25 months (interquartile range 11-50). In the propensity-matched analysis, the risk of all-cause death during follow-up was higher in the group with elevated hs-cTnI group than in the normal group (12.7% vs 6.3%; hazard ratio [HR], 2.67; 95% confidential interval [CI], 1.04-6.82; p = 0.04). In the propensity-matched analysis of preoperative hs-cTnI levels, we found no significant difference between the groups in the rate of all-cause death (12.9% vs. 11.9%; HR, 1.06; 95% CI, 0.45-2.50; p = 0.89). In the postoperative propensity-matched analysis, all-cause death was higher in patients with elevated hs-cTnI than in those with normal levels (14.9% vs. 5.9%; HR, 2.80; 95% CI, 1.01-7.77; p = 0.048). CONCLUSION: In revascularized coronary patients who underwent noncardiac surgery, postoperative (but not preoperative) hs-cTnI elevation was associated with all-cause death during follow-up. Larger datasets are needed to support this finding.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2019) conducted a cohort in Revascularized coronary patients undergoing noncardiac surgery. Postoperative high-sensitivity cardiac troponin I elevation vs. Normal postoperative high-sensitivity cardiac troponin I levels was evaluated on All-cause death during the follow-up period (HR 2.80, 95% CI 1.01-7.77, p=0.048). Postoperative high-sensitivity cardiac troponin I elevation in revascularized coronary patients undergoing noncardiac surgery was associated with increased all-cause death (HR 2.80; 95% CI 1.01-7.77; p=0.048).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: